HealthLinx Obtains UK Patent for OvPlex Ovarian Cancer Diagnostic

The patent is the first granted to the company for its OvPlex test, which uses a five-protein panel to aid early diagnoses of ovarian cancer in symptomatic women.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.